menu
    • menu
    [{"orgOrder":0,"company":"Medac","sponsor":"Fresenius Kabi AG","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"GERMANY","productType":"Large molecule","year":"2020","type":"Agreement","leadProduct":"Adalimumab","moa":"TNF alpha","graph1":"Immunology","graph2":"Approved","graph3":"Medac","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Medac \/ Fresenius Kabi","highestDevelopmentStatusID":"12","companyTruncated":"Medac \/ Fresenius Kabi"},{"orgOrder":0,"company":"Medac","sponsor":"Byondis","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"(vic-) Trastuzumab Duocarmazine","moa":"HER2 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Medac","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Medac \/ Medac","highestDevelopmentStatusID":"10","companyTruncated":"Medac \/ Medac"},{"orgOrder":0,"company":"Medac","sponsor":"Glycostem Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2022","type":"Licensing Agreement","leadProduct":"GTA002","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medac","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Medac \/ Medac GmbH","highestDevelopmentStatusID":"7","companyTruncated":"Medac \/ Medac GmbH"},{"orgOrder":0,"company":"Medac","sponsor":"UroGen Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Small molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Mitomycin","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Medac","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Medac \/ UroGen Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Medac \/ UroGen Pharma"},{"orgOrder":0,"company":"Nippon Medac","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Methotrexate","moa":"DHFR","graph1":"Immunology","graph2":"Approved FDF","graph3":"Nippon Medac","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Nippon Medac \/ Nippon Medac","highestDevelopmentStatusID":"15","companyTruncated":"Nippon Medac \/ Nippon Medac"},{"orgOrder":0,"company":"Nippon Medac","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Methotrexate","moa":"DHFR","graph1":"Immunology","graph2":"Approved FDF","graph3":"Nippon Medac","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Nippon Medac \/ Nippon Medac","highestDevelopmentStatusID":"15","companyTruncated":"Nippon Medac \/ Nippon Medac"},{"orgOrder":0,"company":"Medac","sponsor":"Medexus Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Treosulfan","moa":"||DNA cross-linking","graph1":"Oncology","graph2":"Approved FDF","graph3":"Medac","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Medac \/ Medac","highestDevelopmentStatusID":"15","companyTruncated":"Medac \/ Medac"},{"orgOrder":0,"company":"Medac","sponsor":"Eisai","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Methotrexate","moa":"DHFR","graph1":"Immunology","graph2":"Approved FDF","graph3":"Medac","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Medac \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"Medac \/ Eisai"},{"orgOrder":0,"company":"Medac","sponsor":"Medexus Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cytotoxic Drug","year":"2021","type":"Licensing Agreement","leadProduct":"Treosulfan","moa":"||DNA cross-linking","graph1":"Oncology","graph2":"Approved FDF","graph3":"Medac","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Medac \/ Medexus Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Medac \/ Medexus Pharmaceuticals"},{"orgOrder":0,"company":"Medac","sponsor":"Medexus Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cytotoxic Drug","year":"2021","type":"Licensing Agreement","leadProduct":"Treosulfan","moa":"||DNA cross-linking","graph1":"Oncology","graph2":"Approved FDF","graph3":"Medac","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Medac \/ Medexus Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Medac \/ Medexus Pharmaceuticals"}]

    Find Clinical Drug Pipeline Developments & Deals by Medac

    Menu

    Medac

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Nippon Medac

                            Japan arrow
                            PharmScience R&D
                            Not Confirmed

                            Nippon Medac

                            Japan arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Methotrexate

                            Therapeutic Area : Immunology

                            Study Phase : Approved FDF

                            Recipient : Eisai

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Metoject® Subcutaneous Injection Pen Approved in Japan for methotrexate Treatment

                            Details : Metoject subcutaneous injection pen (methotrexate) works by inhibiting dihydrofolic acid reductase enzyme. It is approved for the treatment of rheumatoid arthritis.

                            Product Name : Metoject

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            February 15, 2024

                            Lead Product(s) : Methotrexate

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved FDF

                            Recipient : Eisai

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Medac

                            Germany arrow
                            PharmScience R&D
                            Not Confirmed

                            Medac

                            Germany arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mitomycin

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : UroGen Pharma

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Merck Announces Positive Data for V116, a 21-Valent Pneumococcal Vaccine for Adults

                            Details : Under the agreement, UroGen will develop a next-generation novel mitomycin-based formulation, UGN-103, UroGen’s RTGel® technology combined with medac’s licensed mitomycin, for urothelial cancers.

                            Product Name : UGN-103

                            Product Type : Small molecule

                            Upfront Cash : Undisclosed

                            January 17, 2024

                            Lead Product(s) : Mitomycin

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : UroGen Pharma

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Nippon Medac

                            Japan arrow
                            PharmScience R&D
                            Not Confirmed

                            Nippon Medac

                            Japan arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Methotrexate

                            Therapeutic Area : Immunology

                            Study Phase : Approved FDF

                            Recipient : Eisai

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Metoject® Subcutaneous Injection Syringe (Methotrexate) Launched in Japan for Rheumatoid Arthritis

                            Details : Metoject will be the first self-administrable MTX subcutaneous injection formulation for rheumatoid arthritis in Japan. It is approved in approximately 50 countries, primarily in Europe.

                            Product Name : Metoject

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            November 16, 2022

                            Lead Product(s) : Methotrexate

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved FDF

                            Recipient : Eisai

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Medac

                            Germany arrow
                            PharmScience R&D
                            Not Confirmed

                            Medac

                            Germany arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Methotrexate

                            Therapeutic Area : Immunology

                            Study Phase : Approved FDF

                            Sponsor : Eisai

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Metoject® Subcutaneous Injection Syringe (Methotrexate) Approved in Japan for Rheumatoid Arthritis

                            Details : Primary endpoint of ACR20 response* at 12 weeks was 59.6% in Metoject (Methotrexate) group versus 51.0% in oral MTX group, indicating comparable efficacy. Adverse drug reaction incidence rates in this trial were 25.0% in the Metoject group and 34.0% in t...

                            Product Name : Metoject

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            September 26, 2022

                            Lead Product(s) : Methotrexate

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved FDF

                            Sponsor : Eisai

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Medac

                            Germany arrow
                            The Generic Rx Session
                            Not Confirmed

                            Medac

                            Germany arrow
                            The Generic Rx Session
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GTA002,Cyclophosphamide,Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Recipient : Glycostem Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Glycostem and Medac Enter Into License, Manufacturing, Supply and Commercialization Agreement for Glycostem's ...

                            Details : Under the terms of the agreement, medac receives an exclusive license to commercialize oNKord® (GTA002) in the EU, the UK and further European countries for acute myeloid leukemia (AML) and multiple myeloma (MM) patients.

                            Product Name : oNKord

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            August 01, 2022

                            Lead Product(s) : GTA002,Cyclophosphamide,Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Recipient : Glycostem Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Medac

                            Germany arrow
                            BioAsia
                            Not Confirmed

                            Medac

                            Germany arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : (vic-) Trastuzumab Duocarmazine

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Recipient : Byondis

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            EMA Validates Marketing Authorization Application for Trastuzumab Duocarmazine (SYD985) in HER2-Positive Metas...

                            Details : Antibody part of SYD985 (trastuzumab duocarmazine) binds to HER2 on surface of cancer cell and the ADC is internalized by cell. After proteolytic cleavage of linker, the inactive cytotoxin is activated and DNA damage is induced, resulting in tumor cell d...

                            Product Name : SYD985

                            Product Type : Large molecule

                            Upfront Cash : Not Applicable

                            July 18, 2022

                            Lead Product(s) : (vic-) Trastuzumab Duocarmazine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Recipient : Byondis

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Medac

                            Germany arrow
                            PharmScience R&D
                            Not Confirmed

                            Medac

                            Germany arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Treosulfan,Fludarabine

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Recipient : Medexus Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Treosulfan Pivotal Study Results Published

                            Details : Study found event-free survival and overall survival superior after Trecondyv (treosulfan) compared to RIC busulfan, also found non-relapse mortality lower in treosulfan arm than busulfan arm.

                            Product Name : Trecondyv

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            June 06, 2022

                            Lead Product(s) : Treosulfan,Fludarabine

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Recipient : Medexus Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Medac

                            Germany arrow
                            PharmScience R&D
                            Not Confirmed

                            Medac

                            Germany arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Treosulfan,Fludarabine

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Medexus Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Medexus Pharmaceuticals and medac GmbH enter into Licensing Agreement for First-in-Class Conditioning Agent, T...

                            Details : Treosulfan will be marketed in Canada under the brand name Trecondyv® and indicated in combination with fludarabine as part of a conditioning treatment prior to allogeneic hematopoietic stem cell transplantation (“allo-HSCT”).

                            Product Name : Trecondyv

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Undisclosed

                            July 12, 2021

                            Lead Product(s) : Treosulfan,Fludarabine

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Medexus Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Medac

                            Germany arrow
                            PharmScience R&D
                            Not Confirmed

                            Medac

                            Germany arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Treosulfan,Fludarabine

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Medexus Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Medexus and Medac Enter Into a License Agreement for Treosulfan, in the United States

                            Details : Medac intends to leverage its strong, existing commercial infrastructure in the United States to address the underserved allo-HSCT market through its commercialization of treosulfan.

                            Product Name : Trecondyv

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Undisclosed

                            February 02, 2021

                            Lead Product(s) : Treosulfan,Fludarabine

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Medexus Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Medac

                            Germany arrow
                            BioAsia
                            Not Confirmed

                            Medac

                            Germany arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Adalimumab

                            Therapeutic Area : Immunology

                            Study Phase : Approved

                            Sponsor : Fresenius Kabi AG

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Fresenius Kabi Enters Marketing Agreement For Biosimilar Product

                            Details : Medac’s sales representatives will begin offering the adalimumab biosimilar IDACIO® as an additional therapy option to the rheumatologists and dermatologists they work with.

                            Product Name : Undisclosed

                            Product Type : Large molecule

                            Upfront Cash : Undisclosed

                            May 28, 2020

                            Lead Product(s) : Adalimumab

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved

                            Sponsor : Fresenius Kabi AG

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth